ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BGNE BeiGene Ltd

156.39
1.31 (0.84%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 104,129
Bid Price 150.53
Ask Price 160.00
News -
Company Name Stock Ticker Symbol Market Type
BeiGene Ltd BGNE NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
1.31 0.84% 156.39 20:00:00
Open Price Low Price High Price Close Price Prev Close
157.00 155.09 157.38 156.39 155.08
Trades Volume VWAP Dollar Volume Avg Volume
2,995 104,129  156.50  16,295,798 -
Last Trade Time Type Quantity Stock Price Currency
16:05:32 1  155.51 USD

BeiGene (BGNE) Options Flow Summary

Overall Flow

Bearish

Net Premium

-11M

Calls / Puts

0.00%

Buys / Sells

66.67%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

BeiGene Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
19.43B 1.36B - 2.46B -881.71M -0.65 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News BeiGene

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BGNE Message Board. Create One! See More Posts on BGNE Message Board See More Message Board Posts

BGNE Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

Your Recent History

Delayed Upgrade Clock